After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017.
Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
Comments
Log in or sign up to join the conversation.